HIG1 hypoxia inducible domain family member 1BGenealiases: CLST11240 · CLST11240-15
Q-omics provides the consensus-scored HIGD1B profile across patient tissues and cancer cell-line models. HIGD1B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, HIGD1B is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, HIGD1B RNA expression shows 15,360 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, LUAD, and TGCT as cancer lineages where HIGD1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HIGD1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HIGD1B survival associations across molecular data types. HIGD1B RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HIGD1B RNA expression–survival associations across cancer types. High HIGD1B expression shows unfavorable associations in KIRP, LUSC, ACC and COAD, but favorable associations in THCA and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for HIGD1B RNA expression.
This table summarizes HIGD1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for HIGD1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HIGD1B shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC, LIHC, THCA and HNSC. The LUAD box plot shows higher HIGD1B RNA expression in normal versus tumor tissue (log2 FC = −3.820, t-test p < 0.001).
This table shows molecular features associated with HIGD1B in patient tissues and cancer cell lines. In patient samples, HIGD1B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, HIGD1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
